强力定眩胶囊联合甲磺酸倍他司汀片治疗眩晕症临床研究

Clinical Study on Qiangli Dingxuan Capsules Combined with Betahistine Mesilate Tablets for Vertigo

目的:观察强力定眩胶囊联合甲磺酸倍他司汀片治疗眩晕症的临床效果。方法:将88例眩晕症患者按随机数字表法分为观察组和对照组各44例。2组均给予护理干预,对照组给予甲磺酸倍他司汀片治疗,观察组在对照组基础上给予强力定眩胶囊治疗。比较2组临床疗效,检测治疗前后血流动力学指标及血清中人降钙素基因相关肽(CGRP)、内皮素-1 (ET-1)水平,观察不良反应发生情况。结果:观察组总有效率为95.45%,高于对照组77.27%,差异有统计学意义(P<0.05)。治疗后,2组基底动脉(BA)、右椎动脉(RVA)以及左椎动脉(LVA)血流速度较治疗前升高(P<0.05),且观察组BA、RVA及LVA血流速度均高于对照组(P<0.05)。治疗后,2组CGRP水平较治疗前升高,ET-1水平较治疗前降低(P<0.05);且观察组CGRP水平高于对照组,ET-1水平低于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:强力定眩胶囊联合甲磺酸倍他司汀片治疗眩晕症可有效缓解患者头晕等临床症状,改善血流动力学指标,疗效显著。

Objective: To observe the clinical effect of Qiangli Dingxuan capsules combined with betahistine mesilate tablets for vertigo. Methods:A total of 88 cases patients with vertigo were divided into the observation group and the control group according to the random number table method,44 cases in each group. Both groups were given nursing intervention;the control group was given betahistine mesilate tablets,and the observation group was additionally given Qiangli Dingxuan capsules based on the treatment of the control group. The clinical effect was compared between the two groups.Hemodynamics indexes as well as levels of human calcitonin gene-related peptide(CGRP) and endothelin-1(ET-1) in serum before and after treatment were detected. The incidence of adverse reactions was observed. Results:The total effective rate was 95.45% in the observation group, higher than that of 77.27% in the control group, the difference being significant(P<0.05). Before treatment,when compared blood flow velocity of basilar artery(BA),right vertebral artery(RVA),and left vertebral artery(LVA) between the two groups,there was no significance in the difference(P>0.05). After treatment,blood flow velocity of basilar artery(BA),right vertebral artery(RVA),and left vertebral artery(LVA) in the two groups was increased when compared with that before treatment(P<0.05),and blood flow velocity of the arteries above in the observation group was higher than that in the control group(P<0.05). After treatment,levels of CGRP in the two groups were increased when compared with those before treatment,and levels of ET-1 were decreased(P<0.05);level of CGRP in the observation group was higher than that in the control group,and level of ET-1 was lower(P<0.05). There was no significant difference being found in the comparison of the incidence of adverse reactions between the two groups(P>0.05). Conclusion: In the treatment of vertigo, the therapy of Qiangli Dingxuan capsules combined with betahistine mesilate tablets can effectively relieve clinical symptoms like dizziness,and improve hemodynamics indexes,with significant curative effect.